Scientists at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have made a surprising discovery: antibodies can have opposite effects on viral infections in human cells.

The spike protein of SARS-CoV-2, the virus that causes COVID-19, enables the virus to enter human cells and is the primary target for the body’s antibodies. Previous research has shown that antibodies can either block the virus, have no effect, or, in rare cases, assist the virus in infecting cells. While antibody drugs work to block infections, this new study challenges current understanding of their mechanisms.

Published in the journal PLOS Pathogens, this study is the first to identify an antibody that can both a...

When cars, planes, ships or computers are built from a material that functions as both a battery and a load-bearing structure, the weight and energy consumption are radically reduced...

An AI-powered tool can distinguish dark matter’s elusive effects from other cosmic phenomena, which could bring us closer to unlocking the secrets of dark matter.

Dark matter is the invisible force holding the universe together – or so we think. It makes up around 85% of all matter and around 27% of the universe’s contents, but since we can’t see it directly, we have to study its gravitational effects on galaxies and other cosmic structures. Despite decades of research, the true nature of dark matter remains one of science’s most elusive questions.

According to a leading theory, dark matter might be a type of particle that barely interacts with anything else, except through gravity...

Drugs for the K-Ras oncogene inspire an approach for targeting the GTPases, a family of enzymes whose dysfunction can lead to Parkinson’s and many other diseases.

UCSF scientists have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases from Parkinson’s to cancer and have long been thought to be “undruggable.”

Because of their slippery exteriors, the GTPases have remained largely out of reach of modern drug discovery, with the exception of the notorious cancer-causing GTPase called K-Ras.

On a hunch, the team tested a dozen drugs that target K-Ras against a handful of GTPases they had mutated to mak...